Viatris Inc. (VTRS)
VTRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/0001792044-26-000013-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VTRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001792044 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.3B |
| Net income | -$3.5B |
| Operating income | -$2.7B |
| Net margin | -24.6% |
| Operating margin | -18.6% |
| Revenue growth | -3.0% |
| Cash | $1.3B |
| Total assets | $37.2B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $1.8B cash; operating cash flow $621.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,146,454,729 (2026-11-02); 1,151,769,872 a year earlier; 1,199,671,000 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Pittsburgh, Pennsylvania, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2K, sold $1.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.7B | -$325.3M | $899.4M | $1.8B | $13.3B | $14.7B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $3.8B | -$118.8M | $381.8M | $886.5M | $13.4B | $14.7B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $3.5B | $176.4M | $388.3M | $1.8B | $14.3B | $14.6B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $3.7B | Not filed | $815.8M | $1.3B | $14.4B | $14.3B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $3.8B | -$128.2M | $744.9M | $975.3M | $14.4B | $14.1B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $3.6B | -$4.6M | $219.7M | $566.4M | $14.5B | $14.1B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $3.3B | -$3.0B | $535.5M | $755.0M | $14.2B | $14.3B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $3.5B | Not filed | $482.7M | $734.8M | $14.0B | $14.7B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-15 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-02 |
Source: SEC EDGAR submissions feed, 547 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.6% |
| 1 month | +20.7% |
| 3 months | +29.8% |
| Year to date | +67.2% |
| 1 year | +90.8% |
| From 52-week high | -1.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $239.77 | -0.74% | $15.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier